English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

18 F-DCFPyL (2-(3-{1-carboxy-5-[(6- 18 F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) is a promising PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA). We present our experience with this single-academic-center prospective study evaluating the positivity rate of 18 F-DCFPyL PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC). Methods: We prospectively enrolled 72 men (52-91 y old; mean ± SD, 71.5 ± 7.2) with BCR after primary definitive treatment with prostatectomy ( n = 42) or radiotherapy ( n = 30). The presence of lesions compatible with PC was evaluated by 2 independent readers. Fifty-nine patients had scans concurrent with at least one other conventional scan: bone scanning (24), CT (21), MR (20), 18 F-fluciclovine PET/CT (18), or 18 F-NaF PET (14). Findings from 18 F-DCFPyL PET/CT were compared with those from other modalities. Impact on patient management based on 18 F-DCFPyL PET/CT was recorded from clinical chart review. Results:  18 F-DCFPyL PET/CT had an overall positivity rate of 85%, which increased with higher prostate-specific antigen (PSA) levels (ng/mL): 50% (PSA &lt; 0.5), 69% (0.5 ≤ PSA &lt; 1), 100% (1 ≤ PSA &lt; 2), 91% (2 ≤ PSA &lt; 5), and 96% (PSA ≥ 5). 18 F-DCFPyL PET detected more lesions than conventional imaging. For anatomic imaging, 20 of 41 (49%) CT or MRI scans had findings congruent with 18 F-DCFPyL, whereas 18 F-DCFPyL PET was positive in 17 of 41 (41%) cases with negative CT or MRI findings. For bone imaging, 26 of 38 (68%) bone or 18 F-NaF PET scans were congruent with 18 F-DCFPyL PET, whereas 18 F-DCFPyL PET localized bone lesions in 8 of 38 (21%) patients with negative results on bone or 18 F-NaF PET scans. In 8 of 18 (44%) patients, 18 F-fluciclovine PET had located the same lesions as did 18 F-DCFPyL PET, whereas 5 of 18 (28%) patients with negative 18 F-fluciclovine findings had positive 18 F-DCFPyL PET findings and 1 of 18 (6%) patients with negative 18 F-DCFPyL findings had uptake in the prostate bed on 18 F-fluciclovine PET. In the remaining 4 of 18 (22%) patients, 18 F-DCFPyL and 18 F-fluciclovine scans showed different lesions. Lastly, 43 of 72 (60%) patients had treatment changes after 18 F-DCFPyL PET and, most noticeably, 17 of these patients (24% total) had lesion localization only on 18 F-DCFPyL PET, despite negative results on conventional imaging. Conclusion:  18 F-DCFPyL PET/CT is a promising diagnostic tool in the work-up of biochemically recurrent PC, given the high positivity rate as compared with Food and Drug Administration-approved currently available imaging modalities and its impact on clinical management in 60% of patients.

the journal of nuclear medicine

Prospective Evaluation of <sup>18</sup>F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management

Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management

Prospective Evaluation of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management